Blitzima - patient leaflet, side effects, dosage

B. PACKAGE LEAFLET

Package leaflet: Information for the patient

Blitzima 100 mg concentrate for solution for infusion Blitzima 500 mg concentrate for solution for infusion

rituximab

• ▼ This medicine is subject to additional monitoring. This will allow quick identification of new safetyinformation. You canhelp by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read this leaflet carefully before you start taking this medicine because it contains important information for you.

• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor, pharmacist or nurse.
• If you get any side effects talk to your doctor, pharmacist or nurse.This includes any possible

side effects not listed in this leaflet. See section 4.

What is in this leaflet:

• 1. What Blitzima is and what it is used for

• 2. What you need to know before you use Blitzima

• 3. How to use Blitzima

• 4. Possible side effects

• 5. How to store Blitzima

• 6. Contents of the pack and other information

1. What Blitzima is and what it is used for

What Blitzima is

Blitzima contains the active substance “rituximab”.This is a type of protein called a “monoclonal antibody”. It sticks to the surface of a type of white blood cell called “B-Lymphocyte”. When rituximab sticks to the surface of this cell, the cell dies.

What Blitzima is used for

Blitzima may be used for the treatment of several different conditions in adults and children. Your doctor may prescribe Blitzima for the treatment of:

• a) Non-Hodgkin’s Lymphoma

his is a disease of the lymph tissue (part of the immune system) that affects a type of white blood cell called B-Lymphocytes.

In adults, Blitzima can be given alone or with other medicines called “chemotherapy”.

In adult patients where the treatment is working, Blitzima may be continued for 2 years after completing the initial treatment.

In children and adolescents, Blitzima is given in combination with “chemotherapy”.

• b) Chronic lymphocytic leukaemia

Chronic lymphocytic leukaemia (CLL) is the most common form of adult leukaemia. CLL affects a particular lymphocyte, the B cell, which originates from the bone marrow and develops in the lymph nodes. Patients with CLL have too many abnormal lymphocytes, which accumulate mainly in the bone marrow and blood.The proliferation of these abnormal B-lymphocytes is the cause of symptoms you may have. Blitzima in combination with chemotherapy destroys these cells which are gradually removed from the body by biological processes.

• c) Granulomatosis with polyangiitis or microscopic polyangiitis

Blitzima is used for the treatment of adults and children 2 years of age and older with granulomatosis with polyangiitis (formerly called Wegener’s gra­nulomatosis) or microscopic polyangiitis, taken in combination with corticosteroids. Granulomatosis with polyangiitis and microscopic polyangiitis are two forms of inflammation of the blood vessels which mainly affects the lungs and kidneys, but may affect other organs as well. B-lymphocytes are involved in the cause of these conditions.

• d) Pemphigus vulgaris

Blitzima is used for the treatment of patients with moderate to severe pemphigus vulgaris. Pemphigus vulgaris is an autoimmune condition that causes painful blisters on the skin and lining of the mouth, nose, throat and genitals.

2. What you need to know before you use Blitzima

Do not take Blitzima if:

• you are allergic to rituximab, other proteins which are like rituximab, or any of the other ingredients of this medicine (listed in section 6)
• you have a severe active infection at the moment
• you have a weak immune system
• you have severe heart failure or severe uncontrolled heart disease and have granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris.

Do not have Blitzima if any of the above apply to you. If you are not sure, talk to your doctor, pharmacist or nurse before you are given Blitzima.

Warnings and precautions

Talk to your doctor, pharmacist or nurse before you are given Blitzima if:

• you have ever had or might now have a hepatitis infection. This is because in a few cases, Blitzima could cause hepatitis B to become active again, which can be fatal in very rare cases. Patients who have ever had hepatitis B infection will be carefully checked by their doctor for signs of this infection.
• you have ever had heart problems (such as angina, palpitations or heart failure) or breathing problems.

If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before you are given Blitzima. Your doctor may need to take special care of you during your treatment with Blitzima.

If you have granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris also tell your doctor

• if you think you may have an infection, even a mild one like a cold. The cells that are affected by Blitzima help to fight infection and you should wait until the infection has passed before you are given Blitzima. Also please tell your doctor if you had a lot of infections in the past or suffer from severe infections.
• if you think you may need any vaccinations in the near future, including vaccinations needed to travel to other countries. Some vaccines should not be given at the same time as Blitzima or in the months after you receive Blitzima. Your doctor will check if you should have any vaccines before you receive Blitzima.

Children and adolescents

Non-Hodgkin’s lymphoma

Blitzima can be used for the the treatment of children and adolescents, 6 months of age and older, with non-Hodgkin’s lymphoma, specifically CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).

Talk to your doctor, pharmacist or nurse before you are given this medicine if you, or your child, are under 18 years of age.

Granulomatosis with polyangiitis or microscopic polyangiitis

Blitzima can be used for treatment of children and adolescents, 2 years of age and older, with granulomatosis with polyangiitis (formerly called Wegener’s gra­nulomatosis) or microscopic polyangiitis. There is not much information about the use of Blitzima in children and adolescents with other diseases.

Talk to your doctor, pharmacist or nurse before you are given this medicine if you, or your child, are under 18 years of age.

Other medicines and Blitzima

Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription and herbal medicines. This is because Blitzima can affect the way some other medicines work. Also some other medicines can affect the way Blitzima works.

In particular, tell your doctor:

• if you are taking medicines for high blood pressure. You may be asked not to take these other medicines 12 hours before you are given Blitzima. This is because some people have a fall in their blood pressure while they are being given Blitzima.
• if you have ever taken medicines which affect your immune system – such as chemotherapy or immune-suppressive medicines.

If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before you are given Blitzima.

Pregnancy and breast-feeding

You must tell your doctor or nurse if you are pregnant, think that you might be pregnant or are planning to become pregnant. This is because Blitzima can across the placenta and may affect your baby.

If you can get pregnant, you and your partner must use an effective method of contraception while using Blitzima. You must also do this for 12 months after your last treatment with Blitzima.

Blitzima passes into breast milk in small amounts. As the long-term effects on breastfed infants are not known, breastfeeding is not recommended during treatment with Blitzima and for 12 months after the treatment..

Driving and using machines

It is not known whether Blitzima has an effect on you being able to drive or use any tools or machines.

Blitzima contains sodium

This medicine contains 52.6 mg sodium (main component of cooking/table salt) in each 10 mL vial and 263.2 mg sodium (main component of cooking/table salt) in each 50 mL vial.

This is equivalent to 2.6% (for 10 mL vial) and 13.2% (for 50 mL vial) of the recommended maximum daily dietary intake of sodium for an adult.

• 3. How Blitzima is given

How it is given

Blitzima will be given to you by a doctor or nurse who is experienced in the use of this treatment.

They will watch you closely while you are being given this medicine. This is in case you get any side effects.

You will always be given Blitzima as a drip (intravenous infusion).

Medicines given before each Blitzima administration

Before you are given Blitzima, you will be given other medicines (pre-medication) to prevent or reduce possible side effects.

How much and how often you will receive your treatment

• a) If you are being treated for non-Hodgkin’s Lymphoma

• If you are having Blitzima alone

Blitzima will be given to you once a week for 4 weeks. Repeated treatment courses with Blitzima are possible.

• If you are having Blitzima with chemotherapy

Blitzima will be given to you on the same day as your chemotherapy. This is usually given every 3 weeks up to 8 times.

• If you respond well to treatment, you may be given Blitzima every 2 or 3 months for two years. Your doctor may change this, depending on how you respond to the medicine.
• If you are less than 18 years of age, you will be given Blitzima with chemotherapy. You will receive Blitzima up to 6 times over a 3.5 – 5.5 month period.

• b) If you are being treated for chronic lymphocytic leukaemia

When you are treated with Blitzima in combination with chemotherapy, you will receive Blitzima infusions on day 0 cycle 1 then day 1 of each cycle for 6 cycles in total. Each cycle has a duration of 28 days. The chemotherapy should be given after the Blitzima infusion. Your doctor will decide if you should receive concomitant supportive therapy.

• c) If you are being treated for granulomatosis with polyangiitis or microscopic polyangiitis Treatment with Blitzima uses four separate infusions given at weekly intervals. Corticosteroids will usually be given by injection before the start of Blitzima treatment. Corticosteroids given by mouth may be started at any time by your doctor to treat your condition. If you are 18 years of age and older and respond well to treatment, you may be given Blitzima as a maintenance treatment. This will be administered as 2 separate infusions which are given 2 weeks apart, followed by 1 infusion every 6 months for at least 2 years. Your doctor may decide to treat you longer with Blitzima (up to 5 years), depending on how you respond to the medicine.

• d) If you are being treated for pemphigus vulgaris

Each course of treatment is made up of two separate infusions which are given 2 weeks apart. If you respond well to treatment, you may be given Blitzima as a maintenance treatment. This will be administered 1 year and 18 months after the initial treatment and then every 6 months as needed or your doctor may change this, depending on how you respond to the medicine.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Most side effects are mild to moderate but some may be serious and require treatment. Rarely, some of these reactions have been fatal.

Infusion reactions

During or within the first 24 hours of the infusion you may develop fever, chills and shivering. Less frequently, some patients may experience pain at the infusion site, blisters, itching, sickness (nausea), tiredness, headache, breathing difficulties, blood pressure raised, wheezing, throat discomfort, tongue or throat swelling, itchy or runny nose, vomiting, flushing or palpitations, heart attack or low number of platelets. If you have heart disease or angina, these reactions might get worse. Tell the person giving you the infusion immediately if you or your child develops any of these symptoms, as the infusion may need to be slowed down or stopped. You may require additional treatment such as an antihistamine or paracetamol. When these symptoms go away, or improve, the infusion can be continued. These reactions are less likely to happen after the second infusion. Your doctor may decide to stop your Blitzima treatment if these reactions are serious.

Infections

Tell your doctor immediately if you or your child gets signs of an infection including:

• fever, cough, sore throat, burning pain when passing urine or feeling weak or generally unwell
• memory loss, trouble thinking, difficulty walking or sight loss – these may be due to a very rare,

serious brain infection, which has been fatal (progressive multifocal leukoencephalopathy or PML).

You might get infections more easily during your treatment with Blitzima.

These are often colds, but there have been cases of pneumonia or urinary infections. These are listed below under “Other side effects”.

If you are being treated for granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris, you will also find this information in the Patient Alert Card you have been given by your doctor. It is important that you keep this Alert Card and show it to your partner or caregiver.

Skin reactions

Very rarely, severe blistering skin conditions that can be life-threatening may occur. Redness, often associated with blisters, may appear on the skin or on mucous membranes, such as inside the mouth, the genital areas or the eyelids, and fever may be present. Tell your doctor immediately if you have any of these symptoms.

Other side effects include:

• a) If you or your child are being treated for non-Hodgkin’s Lymphoma or chronic lymphocytic leukaemia

Very common side effects (may affect more than 1 in 10 people):

• bacterial or viral infections, bronchitis
• low number of white blood cells, with or without fever or blood cells called “platelets”
• feeling sick (nausea)
• bald spots on the scalp, chills, headache
• lower immunity – because of lower levels of anti-bodies called “immunoglobulin­s” (IgG)

in the blood which help protect against infection

Common side effects (may affect up to 1 in 10 people):

• infections of the blood (sepsis), pneumonia, shingles, cold, bronchial tube infections, fungal infections, infections of unknown origin, sinus inflammation, hepatitis B
• low number of red blood cells (anaemia), low number of all blood cells
• allergic reactions (hypersensitivity)
• high blood sugar level, weight loss, swelling in the face and body, high levels of the enzyme “lactate dehydrogenase (LDH)” in the blood, low calcium levels in the blood
• unusual feelings of the skin – such as numbness, tingling, pricking, burning, a creeping skin feeling, reduced sense of touch
• feeling restless, problems falling asleep,
• becoming very red in the face and other areas of the skin as a consequence of dilation of the blood vessels
• feeling dizzy or anxious
• producing more tears, tear duct problems, inflamed eye (conjunctivitis)
• ringing sound in the ears, ear pain
• heart problems – such as heart attack, uneven or fast heart rate
• high or low blood pressure (low blood pressure especially when standing upright)
• tightening of the muscles in the airways which causes wheezing (bronchospasm), inflammation, irritation in the lungs, throat or sinuses, being short of breath, runny

nose

• being sick (vomiting), diarrhoea, pain in the stomach, irritation or ulcers in the throat and mouth, problems swallowing, constipation, indigestion
• eating disorders, not eating enough, leading to weight loss
• hives, increased sweating, night sweats
• muscle problems – such as tight muscles, joint or muscle pain, back and neck pain
• general discomfort or feeling uneasy or tired, shaking, signs of flu
• multiple-organ failure.

Uncommon side effects (may affect up to 1 in 100 people):

• blood clotting problems, decrease of red blood cell production and increase of red blood cell destruction (aplastic haemolytic anaemia), swollen or enlarged lymph nodes
• low mood and loss of interest or enjoyment in doing things, feeling nervous
• taste problems – such as changes in the way things taste
• heart problems – such as reduced heart rate or chest pain (angina)
• asthma, too little oxygen reaching the body organs
• swelling of the stomach.

Very rare side effects (may affect up to 1 in 10,000 people):

• short term increase in the amount of some types of anti-bodies in the blood (called immunoglobulins – IgM), chemical disturbances in the blood caused by break-down of dying cancer cells
• nerve damage in arms and legs, paralysed face
• heart failure
• inflammation of blood vessels including those leading to skin symptoms
• respiratory failure
• damage to the intestinal wall (perforation)
• severe skin problems causing blisters that can be life-threatening. Redness, often associated with blisters, may appear on the skin or on mucous membranes, such as inside the mouth, the genital areas or the eyelids, and fever may be present.
• kidney failure
• severe vision loss

Not known (it is not known how often these side effects happen):

• a reduction in white blood cells which does not happen straight away
• reduced platelets number just after the infusion – this can be reversed, but can be fatal in rare cases
• hearing loss, loss of other senses

Children and adolescents with non-Hodgkin’s lym­phoma:

In general, side effects in children and adolescents with non-Hodgkin’s lymphoma were similar to those in adults with non-Hodgkin’s lymphoma or chronic lymphocytic leukaemia. The most common side effects seen were fever associated with low levels of a type of white blood cell (neutrophil), inflammation or sores in the lining of the mouth, and allergic reactions (hypersensitivity).

• b) If you or your child are being treated for granulomatosis with polyangiitis or microscopic polyangiitis

Very common side effects (may affect more than 1 in 10 people):

• infections, such as chest infections, urinary tract infections (pain on passing water), colds and herpes infections
• allergic reactions that are most likely to occur during an infusion, but can occur up to 24-hours after infusion
• diarrhoea
• coughing or shortness of breath
• nose bleeds
• raised blood pressure
• painful joints or back
• muscle twitches or shakiness
• feeling dizzy
• tremors (shakiness, often in the hands)
• difficulty sleeping (insomnia)
• swelling of the hands or ankles

Common side effects (may affect up to 1 in 10 people):

• indigestion
• constipation
• skin rashes, including acne or spots
• flushing or redness of the skin
• fever
• blocked or runny nose
• tight or painful muscles
• pain in the muscles or in the hands or feet
• low number of red blood cells (anaemia)
• low numbers of platelets in the blood
• an increase in the amount of potassium in the blood
• changes in the rhythm of the heart, or the heart beating faster than normal

Very rare side effects (may affect up to 1 in 10,000 people):

• severe blistering skin conditions that can be life-threatening. Redness, often associated with blisters, may appear on the skin or on mucous membranes, such as inside the mouth, the genital areas or the eyelids, and fever may be present.
• recurrence of a previous Hepatitis B infection

Children and adolescents with granulomatosis with polyangiitis or microscopic polyangiitis

In general, side effects in children and adolescents with granulomatosis with polyangiitis or microscopic polyangiitis were of a similar type to those in adults with granulomatosis with polyangiitis or microscopic polyangiitis. Most common side effects seen were infections, allergic reactions and feeling sick (nausea).

• c) If you are being treated for pemphigus vulgaris

Very common side effects (may affect more than 1 in 10 people):

• allergic reactions that are most likely to occur during an infusion, but can occur up to 24 hours after infusion
• headache
• infections such as chest infections
• long lasting depression
• loss of hair

Common side effects (may affect up to 1 in 10 people):

• infections such as common cold, herpes infections, eye infection, oral thrush and urinary tract infections (pain on passing urine)
• mood disorders such as irritability and depression
• skin disorders such as itching, hives, and benign lumps
• feeling tired or dizzy
• fever
• painful j oints or back
• pain in the tummy
• pain in the muscles
• heart beating faster than normal

Blitzima may also cause changes in laboratory tests carried out by your doctor.

If you are having Blitzima with other medicines, some of the side effects you may get may be due to the other medicines.

Reporting of side effects

If you get any side effects talk to your doctor, pharmacist or nurse. This includes any side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Blitzima

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and the vial after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C – 8 °C). Keep the container in the outer carton in order to protect from light.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines that you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Blitzima contains

• The active ingredient in Blitzima is called rituximab.

The 10 mL vial contains 100 mg of rituximab (10 mg/mL).

The 50 mL vial contains 500 mg of rituximab (10 mg/mL).

• The other ingredients are sodium chloride, tri-sodium citrate dihydrate, polysorbate 80 and water for injections.

What Blitzima looks like and contents of the pack

Blitzima is a clear, colourless solution, supplied as a concentrate for solution for infusion.

10 mL vial – Pack of 2 vials

50 mL vial – Pack of 1 vial

Marketing Authorisation Holder

Celltrion Healthcare Hungary Kft.

1062 Budapest

Váci út 1–3. WestEnd Office Building B torony

Hungary

Manufacturer

Millmount Healthcare Ltd.

Block 7, City North Business Campus,

Stamullen, Co. Meath K32 YD60, Ireland

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

Belgie/Belgiqu­e/Belgien Mundipharma BV Tél/Tel: + 32 15 45 1180	Lietuva EGIS PHARMACEUTICALS PLC atstovybé Tel: +370 5 231 4658
Etnrapua EGIS Bulgaria EOOD Ten.: + 359 2 987 6040 Česká republika EGIS Praha, spol. s r.o Tel: +420 227 129 111	Luxembourg/Lu­xemburg Mundipharma BV Tél/Tel: + 32 15 45 1180 Magyarország Egis Gyógyszergyár Zrt. Tel.: + 36 1 803 5555
Danmark Orion Pharma A/S Tlf: + 45 86 14 00 00	Malta Mint Health Ltd. Tel: +356 2093 9800
Deutschland Mundipharma GmbH Tel: +49 (0) 69 506029–000	Nederland Mundipharma Pharmaceuticals B.V Tel: + 31 33 450 8270
Eesti Orion Pharma Eesti OÜ Tel: + 372 6 644 550	Norge Orion Pharma AS Tlf: + 47 40 00 42 10
ELLáSa BLANES A.E. Tql: +30 210 8009111 – 120	Österreich Astro-Pharma GmbH Tel: +43 1 97 99 860
España Kern Pharma, S.L. Tel: +34 93 700 2525	Polska EGIS Polska Sp. z o.o. Tel.: + 48 22 417 9200
France CELLTIRION HEALTHCARE FRANCE SAS Tél: +33 (0)1 71 25 27 00	Portugal PharmaKERN Portugal – Produtos Farmacéuticos, Sociedade Unipessoal, Lda. Tel: +351 214 200 290
Hrvatska Oktal Pharma d.o.o. Tel: +385 1 6595 777	Romania Egis Pharmaceuticals PLC Romania Tel: + 40 21 412 0017
Ireland Mundipharma Pharmaceuticals Limited Tel: +353 1 2063800	Slovenija OPH Oktal Pharma d.o.o. Tel: +386 1 519 29 22
Ísland Vistor hf. Sími: +354 535 7000	Slovenská republika EGIS SLOVAKIA spol. s r.o Tel: +421 2 3240 9422
Italia Mundipharma Pharmaceuticals Srl Tel: +39 02 31 82 88 1	Suomi/Finland Orion Pharma Puh/Tel: + 358 10 4261
Kúnpog C.A. Papaellinas Ltd Tql: +357 22741741	Sverige Orion Pharma AB Tel: + 46 8 623 64 40
Latvija	United Kingdom

EGIS Pharmaceuticals PLC parstavnieciba Latvija NAPP Pharmaceutical­s Ltd.

Tel: +371 67613859 Tel: +44 1223 424444

This leaflet was last revised in

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site:

.

78